Karyopharm announce Xpovio meets endpoints in Phase III trial

The pharmaceutical company announced positive top-line results from the randomised Phase III BOSTON study of Xpovio (selinexor). The drug in combination with once-weekly Velcade (bortezomib) and low-dose dexamethasone (SVd) met its primary endpoint of a statistically significant increase in progression-free survival (PFS) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd). The trial saw the

Continue Reading

New clinical trial to investigate affects of CBD on Parkinson’s related psychosis

A pioneering clinical trial is set to investigate the use of cannabidiol (CBD) in people with Parkinson’s-related psychosis. Parkinson’s UK will be partnering with scientists at King’s College London in the first large-scale trial which aims to provide preliminary evidence for the safety and efficacy of CBD to alleviate the symptoms of Parkinson’s-related psychosis, characterised by hallucinations and delusions.

Continue Reading

Novartis treatment achieves positive results in possible new indication

Novartis announced positive results from its Cosentyx focused PREVENT trial, advancing the drug in potential new indication for patients with axial spondyloarthritis. The phase III study met its 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA), showing a considerable and clinically meaningful reduction in disease activity. Novartis has also submitted

Continue Reading

Astellas announce first dosing of patient in late-stage menopause trial

Astellas Pharma has announced the initiation and dosing of the first patient in their SKYLIGHT1 Phase III pivotal trial for fezolinetant. The investigational oral, non-hormonal compound is being studied for the treatment of moderate-to-severe menopause related vasomotor symptoms (VMS), such as hot flashes and night sweats. The first trials of the programme will evaluate the efficacy

Continue Reading